

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61K 31/445, 31/355, 31/375	A1	(11) International Publication Number: WO 96/34606 (43) International Publication Date: 7 November 1996 (07.11.96)
(21) International Application Number: PCT/DK96/00192 (22) International Filing Date: 29 April 1996 (29.04.96) (30) Priority Data: 0523/95 5 May 1995 (05.05.95) DK (71) Applicant (for all designated States except US): NOVO NORDISK A/S [DK/DK]; Novo Allé, DK-2880 Bagsværd (DK). (72) Inventors; and (75) Inventors/Applicants (for US only): SVENSSON, Jørgen, Ryhl [DK/DK]; Borgmestervænget 52, DK-3600 Fredrikssund (DK). NYGAARD, Lars [DK/DK]; Monrads Allé 29, DK-2500 Valby (DK). ANDERSEN, Tina, Meinertz [DK/DK]; Slettevang 3, DK-2970 Hørsholm (DK). WEIBEL, Helle [DK/DK]; Ringridervej 7, DK-3400 Hillerød (DK). HJORTH, Thyge, Borup [DK/DK]; Solbakken 5, DK-3520 Farum (DK). (74) Common Representative: NOVO NORDISK A/S; Corporate Patents, Novo Allé, DK-2880 Bagsværd (DK).		(81) Designated States: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, ARIPO patent (KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
(54) Title: PHARMACEUTICAL COMPOSITION CONTAINING TIAGABINE HYDROCHLORIDE AND THE PROCESS FOR ITS PREPARATION (57) Abstract The present invention provides a new stable pharmaceutical composition containing tiagabine hydrochloride as active ingredient.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Latvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

Pharmaceutical composition containing tiagabine hydrochloride and the process for its preparation

The subject-matter of the present invention is a new pharmaceutical composition containing tiagabine hydrochloride as active ingredient and the process for
5 its preparation.

In the present invention the R-isomer of N-(4,4-di(3-methylthien-2-yl)but-3-enyl-nipecotic acid is referred to by its generic name (INN): tiagabine, which is a well tolerated medication, having antiepileptic activity.

The compound N-(4,4-di(3-methylthien-2-yl)but-3-enyl-nipecotic acid is
10 disclosed in USP 5,010,090.

Various solutions have been proposed for the preparation of medications based on tiagabine hydrochloride.

The aim of the present invention is to supply a new composition intended for the preparation of tiagabine hydrochloride with improved stability, in particular
15 solid dosage forms thereof.

It has been found in fact that tiagabine hydrochloride decomposes in the presence of and in contact with oxygen and water.

Thus, from a first aspect, the subject-matter of the present invention is a pharmaceutical composition intended for the preparation of dosage forms and
20 in particular solid dosage forms containing an efficacious quantity of tiagabine hydrochloride or of one of its pharmaceutically acceptable salts as active ingredient and characterised in that it contains at least one pharmaceutically acceptable antioxidant agent, in a sufficient quantity to stabilise the active ingredient.

Thus the present invention is based on the surprising discovery of the fact that the stability of tiagabine hydrochloride, or of one of its pharmaceutically acceptable salts, can be considerably improved in preparations containing tiagabine hydrochloride or of its pharmaceutically acceptable salts and anti-
5 oxidant agent.

Tiagabine hydrochloride, together with a conventional adjuvant, antioxidant carrier, or diluent, and if desired a pharmaceutically acceptable acid addition salt thereof, may be placed into the form of pharmaceutical compositions and unit dosages thereof, and in such form may be employed as solids, such as
10 tablets or filled capsules, or liquids such as solutions, suspensions, emulsions, elixirs, or capsules filled with the same, all for oral use, in the form of suppositories for rectal administration; or as pessaries for vaginal use; or in the form of sterile injectable solutions for parenteral (including subcutaneous) use.

Within the framework of the present description and of the claims, by pow-
15 ders is meant any mixture of components, granulated or not, intended to be placed in solution and/or in suspension in water, or again to be ingested directly or by any other appropriate means as for example in a mixture with a food product.

In accordance with a particular characteristic of the invention, the granulation
20 is carried out as a melt-granulation.

In accordance with another particular characteristic, this composition also contains pharmaceutically acceptable diluents.

In accordance with a particular characteristic of the invention, the antioxidant agent cited above is selected from among α -tocopherol, γ -tocopherol, δ -to-
25 copherol, extracts of natural origin rich in tocopherol, L-ascorbic acid and its sodium or calcium salts, ascorbyl palmitate, propyl gallate (PG), octyl gallate,

dodecyl gallate, butylated hydroxy anisole (BHA) and butylated hydroxy toluene (BHT).

In accordance with a currently preferred embodiment, the antioxidant agent will be α -tocopherol.

- 5 In accordance with another particular characteristic of the invention, the diluent is lactose and/or polyethylenglycol.

However, any other pharmaceutically acceptable diluents could be used.

The quantities of diluents can be easily determined by a person skilled in the art and depend of course on the final pharmaceutical form required.

- 10 Generally speaking, a composition which complies with the present invention and which are intended for the preparation of tablets, may contain, expressed in parts by weight per 100 parts of tiagabine hydrochloride, or of one of its pharmaceutically acceptable salts:

between 100 and 4000 parts by weight of anhydrous lactose;

- 15 between 1 and 100 parts by weight of an antioxidant, in the case of α -Tocopherol preferably between 1 and 50 parts by weight;

between 50 and 500 parts by weight of pregelatinized starch;

between 1000 and 10000 parts by weight of microcrystalline cellulose;

between 10 and 500 parts by weight of crospovidone;

- 20 between 10 and 500 parts by weight of silicon dioxide;

between 10 and 500 parts by weight of hydrogenated vegetable oil;

between 10 and 500 parts by weight of magnesium stearate;

between 10 and 500 parts by weight of hydroxypropyl methylcellulose;

between 10 and 500 parts by weight of hydroxypropyl cellulose;

- 25 between 1000 and 10000 parts by weight of Mannitol;

between 10 and 500 parts by weight of stearic acid;
between 10 and 500 parts by weight of Titanium Dioxide;

All excipients are of pharmaceutically acceptable grade.

In a preferred composition according to the present invention the amount of 5 antioxidant is between 1 and 50 parts by weight per 100 parts of tiagabine hydrochloride.

In a more preferred composition according to the present invention the type of antioxidant is selected from the fat-soluble antioxidant, and in its most preferred form from α -tocopherol.

10 According to a preferred embodiment of the invention the water content of the excipients is very low. More specifically the water content in the diluents is very low in order to minimize the water content of the pharmaceutical composition. Lactose is used in its anhydrous form.

Furthermore, all excipients may be applied in a dry form, preferably obtained 15 by heating the excipients before mixing, to minimize the water content of the pharmaceutical composition.

In accordance with a second aspect, the subject-matter of the present invention is a pharmaceutical preparation, in the form of tablet or powder, characterised in that it contains a composition as defined previously associ- 20 ated if required with at least one customary additive selected from among the sweeteners, flavouring agents, colours and lubricants.

The choice of these additives and their quantity can easily be determined by a person skilled in the art.

A preferred manufacturing process for pharmaceutical compositions according to the invention is mixing of tiagabine hydrochloride, one or more antioxidants and other pharmaceutical excipients followed by meltgranulation in a high shear mixer. Polyethylene glycols, waxes, stearic acid or other low temperature melting binders can be used. The granules can be filled into capsules, compressed into tablets or used in other pharmaceutical dosage forms.

More preferably the manufacturing process applied is direct compression of tablets, wherein tiagabine hydrochloride, one or more antioxidants and other excipients suitable for direct compression are mixed followed by tableting.

10 Yet, another preferred embodiment of the manufacturing process is wet granulation, where granules are obtained by wet massing of tiagabine hydrochloride, together with one or more antioxidants and other excipients.

The most preferred process includes the melt granulation step whereby tiagabine hydrochloride is kept at conditions of low water vapor pressure.

15 A sweetener may be a natural sugar such as sucrose or sorbitol or a synthetic product such as saccharine or aspartame. Saccharine will be used to advantage.

When the antioxidant selected is α -tocopherol, which is hydrophobic, it can be advantageous to emulsify it in an appropriate solvent such as for example
20 water or an organic solvent compatible with tiagabine hydrochloride.

Various emulsifying agents conventionally used in pharmacy may also be used to create this emulsion.

The present invention will be illustrated with the following non-exhaustive examples.

EXAMPLE 1Tiagabine hydrochloride tablets stabilized with α -Tocopherol.

	Tablet Strengths, mg	8	8
	Tablet Gross Mass, mg	320	320
5	Tiagabine Hydrochloride Monohydrate	8.35	8.35
	Polyethylene Glycol 6000, NF	16.0	16.0
	Lactose, anhydrous, NF	279	279
	α -Tocopherol, Ph. Eur.	0.800	0
	Talc, Ph. Eur.	16.0	16.8

10 Tiagabine hydrochloride monohydrate, α -tocopherol, polyethylene glycol 6000 and anhydrous lactose are blended in a high speed mixer and granulated by melt granulation. After cooling, the granules are blended with talc and compressed into tablets on a tableting machine.

The stability of the tablets is improved compared to tablets without α -
 15 tocopherol. This is seen from stability studies, where the extent of degradation of tiagabine hydrochloride is expressed as the total sum of degradation products. Results are shown in Table 1.

Table 1: Stability of Tiagabine Hydrochloride Tablets.

Sum of degradation products after 18
months stored at 25°C/60% RH.

Tablets with α -tocopherol	0.5 %
5 Tablets without α -tocopherol	1.9 %

EXAMPLE 2

Tiagabine Hydrochloride Tablets stabilized with α -Tocopherol and Ascorbyl Palmitate.

10	Tablet Strengths, mg	8	8
	Tablet Gross Mass, mg	320	320
15	Tiagabine Hydrochloride Monohydrate	8.35	8.35
	Polyethylene Glycol 6000, NF	16.0	16.0
	Lactose, anhydrous, NF	279	279
	α -Tocopherol, Ph. Eur.	0.400	0
	Ascorbyl Palmitate	0.400	0
	Talc, Ph. Eur.	16.0	16.8

Tiagabine hydrochloride monohydrate, α -tocopherol, ascorbyl palmitate, polyethylene glycol 6000 and anhydrous lactose are blended in a high speed mixer and granulated by melt granulation. After cooling, the granules are

blended with talc and compressed into tablets on a tableting machine.

EXAMPLE 3

Filmcoated Tiagabine Hydrochloride Tablets stabilized with α -Tocopherol.

	Tablet Strengths, mg	10	10
5	Tablet Gross Mass, mg	320	320
	Tiagabine Hydrochloride Monohydrate	11.5	11.5
	Polyethylene Glycol 6000, NF	20.0	20.0
	α -Tocopherol, Ph. Eur.	1.10	0
	Talc, Ph. Eur.	16.0	16.0
10	Lactose, anhydrous, NF	up to 320	up to 320

Tiagabine hydrochloride monohydrate, α -tocopherol, polyethylene glycol 6000 and anhydrous lactose are blended in a high speed mixer and granulated by melt granulation. After cooling, the granules are blended with talc and compressed into tablets on a tableting machine.

- 15 In order to protect against light and improve the appearance of the tablets, the tablets are film-coated.

The tablets were coated with the following film-coating composition where an amount of coating material of 5 mg/cm² were chosen as being satisfactory with

respect to stability of the tablets:

Methylhydroxypropylcellulose, Ph. Eur.....	~ 4.34 mg/tablet
Polyethylene Glycol 6000, NF.....	~ 5.20 -
Titanium Dioxide, Ph. Eur.....	~ 1.73 -
5 Purified Water, Ph. Eur.....	q.s. -
Talc, Ph. Eur. (Added as polishing agent at the end of the film-coating process (0.5 % w/w of tablet core). Absorbed amount is not quantified.	

EXAMPLE 4

Filmcoated Tiagabine Hydrochloride Tablets stabilized with α -Tocopherol and
 10 Ascorbyl Palmitate.

15	Tablet Strengths, mg	10	10
	Tablet Gross Mass, mg	320	320
	Tiagabine Hydrochloride Monohydrate	11.5	11.5
	Polyethylene Glycol 6000, NF	20.0	20.0
	α -Tocopherol, Ph. Eur.	0.55	0
	Ascorbyl Palmitate	0.55	0
	Talc, Ph. Eur.	16.0	16.0
	Lactose, anhydrous, NF	up to 320	up to 320

Tiagabine hydrochloride monohydrate, α -tocopherol, ascorbyl palmitate,

polyethylene glycol 6000 and anhydrous lactose are blended in a high speed mixer and granulated by melt granulation. After cooling, the granules are blended with talc and compressed into tablets on a tableting machine.

In order to protect against light and improve the appearance of the tablets, the 5 tablets are film-coated.

The tablets were coated with the following film-coating composition where an amount of coating material of 5 mg/cm² were chosen as being satisfactory with respect to stability of the tablets:

	Methylhydroxypropylcellulose, Ph. Eur.....	~ 4.34 mg/tablet
10	Polyethylene Glycol 6000, NF.....	~ 5.20 -
	Titanium Dioxide, Ph. Eur.....	~ 1.73 -
	Purified Water, Ph. Eur.....	q.s. -
	Talc, Ph. Eur. (Added as polishing agent at the end of the film-coating process (0.5 % w/w of tablet core). Adsorbed amount is not quantified.	

EXAMPLE 5

Tiagabine Hydrochloride Tablets stabilized with α -Tocopherol and Sodium Citrate as chelating agent.

5	Tablet Strengths, mg	8	8
	Tablet Gross Mass, mg	320	320
	Tiagabine Hydrochloride Monohydrate	8.35	8.35
10	Polyethylene Glycol 6000, NF	16.0	16.0
	Lactose, anhydrous, NF	279	279
	α -Tocopherol, Ph. Eur.	0.400	0
	Sodium Citrate	0.400	0
	Talc, Ph. Eur.	16.0	16.8

Tiagabine Hydrochloride monohydrate, α -tocopherol, sodium citrate, polyethylene glycol 6000 and anhydrous lactose are blended in a high speed mixer and granulated by melt granulation. After cooling, the granules are
15 blended with talc and compressed into tablets on a tableting machine.

EXAMPLE 6

Tiagabine Hydrochloride Tablets stabilized with α -Tocopherol and EDTA(*) as chelating agent.

	Tablet Strengths, mg	8	8
5	Tablet Gross Mass, mg	320	320
	Tiagabine Hydrochloride Monohydrate	8.35	8.35
	Polyethylene Glycol 6000, NF	16.0	16.0
	Lactose, anhydrous, NF	279	279
	α -Tocopherol, Ph. Eur.	0.270	0
10	EDTA(*)	0.530	0
	Talc, Ph. Eur.	16.0	16.8

Tiagabine hydrochloride monohydrate, α -tocopherol, EDTA(*), polyethylene glycol 6000 and anhydrous lactose are blended in a high speed mixer and granulated by melt granulation. After cooling, the granules are blended with talc 15 and compressed into tablets on a tableting machine.

(*) EDTA in its form of Disodium Edetate.

EXAMPLE 7Solution containing tiagabine hydrochloride

Composition:

	Tiagabine hydrochloride	1.14 mg
5	Glucose monohydrate	55.0 mg
	Sodium hydroxide 2N	q.s.
	Water	ad 1.00 ml
	α -tocopherol	0.250 mg
	Na-citrate	0.250 mg
10	Ascorbyl Palmitate	0.250 mg

Manufacturing method:

Tiagabine hydrochloride, Na-citrate and the antioxidants are mixed in a flask with water at room temperature by stirring until the substance is soluted (approximately five minutes). Glucose monohydrate is added to the solution by 15 stirring at room temperature for two minutes. At last the pH is adjusted to 7.4 and the solution is diluted with water.

The solution is used for administration of tiagabine hydrochloride as injection and as intravenous infusion. The formulation is also used for nasal and pulmonal delivery and as an oral solution or mixture.

EXAMPLE 8Solution containing tiagabine hydrochloride

Composition:

Tiagabine hydrochloride	1.14 mg
5 Glucose monohydrate	55.0 mg
Sodium hydroxide 2N	q.s.
Water sterile	ad 1.00 ml
α -tocopherol	0.250 mg
Ascorbyl Palmitate	0.250 mg
10 EDTA (Disodium Edetate)	0.500 mg

Manufacturing method:

Tiagabine hydrochloride, the antioxidants and chelating agent are mixed in a flask with water at room temperature by stirring until the substance is soluted (approximately five minutes). Glucose monohydrate is added to the solution by 15 stirring at room temperature for two minutes. At last the pH is adjusted to 7.4 and the solution is diluted with water.

The solution is used for administration of tiagabine hydrochloride as injection and as intravenous infusion. The formulation is also used for nasal and pulmonal delivery and as an oral solution or mixture.

EXAMPLE 9Gel containing tiagabine hydrochloride

Composition:

Tiagabine hydrochloride	1.14 mg
5 Carbomer 940	5.00 mg
Sodium hydroxide 2N	q.s.
Water	ad 1.00 ml
α -tocopherol	0.250 mg
Na-citrate	0.250 mg
10 Ascorbyl Palmitate	0.250 mg

Manufacturing method:

Tiagabine hydrochloride, Na-citrate and the antioxidants are mixed in a flask with water at room temperature by stirring until the substance is soluted (approximately five minutes). While stirring the carbomer is added little by little. To make optimal viscosity sodium hydroxide is added while stirring for five minutes.

The gel is used for dermal, vaginal or rectal administration.

EXAMPLE 10Gel containing tiagabine hydrochloride

Composition:

Tiagabine hydrochloride	1.14 mg
5 Carbomer 940	5.00 mg
Sodium hydroxide 2N	q.s.
Water	ad 1.00 ml
α -tocopherol	0.250 mg
Ascorbyl Palmitate	0.250 mg
10 EDTA (Disodium Edetate)	0.500 mg

Manufacturing method:

Tiagabine hydrochloride, the antioxidants and chelating agent are mixed in a flask with water at room temperature by stirring until the substance is soluted (approximately five minutes). While stirring the carbomer is added little by little. To make optimal viscosity sodium hydroxide was added while stirring for five minutes.

The gel is used for dermal, vaginal or rectal administration.

EXAMPLE 11Influence of metal ions, chelator and antioxidants on Tiagabine hydrochloride stability in solutions

Introduction

- 5 Poor stability of drugs in dosage forms is often detected after storage for several months. On this background a model for fast evaluation of the effect of different excipients was set up.

Introductory studies showed that the model substance selected for the work ($C_{20}H_{28}NO_2S_2Cl$, Tiagabine hydrochloride) could be oxidized. Therefore,

- 10 Hydrogen Peroxide was chosen as an oxidant in order to promote the oxidation process.

Experimental Methods

* Chemicals

- Tiagabine hydrochloride, Lot. no. 9208L 315 (NN) was used for the experi-
15 ments. All other chemicals used were of analytical grade.

* Analytical Method

- HPLC analyses were carried out using a Waters model 501 and 516 pumps equipped with a Waters 490 E UV-detector and a Waters 700 WISP autoinjector. The column, 125 mm/4 mm, was packed with Nucleosil C_{18} (5 μ m). The
20 mobile phase was 0.1% Trifluoroacetic acid in Acetonitrile/water (35:65). Flow was 1.0 ml/min, injection volume 50 μ l, ambient column temperature and detector wavelength 250 nm.

*** Degradation of Tiagabine Hydrochloride in Reference Solutions**

Solutions of tiagabine hydrochloride (100 $\mu\text{g/ml}$ (0.2 $\mu\text{mol/ml}$), containing 60% v/v ethanol in water, was investigated. 1% v/v Hydrogene Peroxide was added to the solution in order to initiate the degradation of tiagabine hydrochloride. The HPLC-vials were tightly closed, and the degradation of tiagabine hydrochloride was followed at Room Temperature or at 50°C. At appropriate intervals injections were performed for HPLC quantification.

*** Degradation of Tiagabine Hydrochloride in Presence of Metal Ions \pm Chelator**

10 In some experiments metal ions were added to the reference solutions in order to study the possibility of the metal ions in catalyzing the degradation of tiagabine hydrochloride. Amounts of metal ions corresponding to 35 ppm (\sim 0.6 $\mu\text{mol/ml}$) of the cations Cr^{2+} , Fe^{3+} , Zn^{2+} , Ni^{2+} , Mg^{2+} , Cu^{2+} or Co^{2+} were added.

15 In other experiments the chelator 250 $\mu\text{g/ml}$ (\sim 0.9 $\mu\text{mol/ml}$) Sodium Citrate were added in order to prevent the catalyzing effect of the metal ions.

*** Degradation of Tiagabine Hydrochloride in Presence of Antioxidants**

Addition of antioxidants to the reference solutions were performed in order to prevent the degradation of tiagabine hydrochloride. The concentrations of antioxidants chosen were as high as possible in the ethanol-water medium. The antioxidants were tested in the tiagabine hydrochloride solutions alone or in combination with other antioxidants.

*** Calculations**

The degradation kinetics followed in all cases a zero order kinetics and consequently the rate constants k_{obs} were calculated as the slope of the curve representing the decrease of tiagabine hydrochloride as function of time.

Results and Discussion

5 Degradation of Tiagabine Hydrochloride in Presence of Metal Ions \pm Chelator

The values given in Table 2 shows the observed 0. order rate constants (k_{obs}) for degradation of tiagabine hydrochloride in solutions. Fe^{3+} and Cr^{2+} catalyzed the degradation of tiagabine hydrochloride, while Zn^{2+} or Ni^{2+} did not have any remarkable effect on the degradation process. The experiment 10 showed that the catalyzing effect of Cr^{2+} and Fe^{3+} was reduced by addition of Sodium Citrate.

Table 2: Degradation of 100 μ g/ml tiagabine hydrochloride, in 1% Hydrogen Peroxide and 60% Ethanol/Water by Adding of 35 ppm Metal Ions, RT

	$K_{obs} (\mu g \cdot ml^{-1} \cdot h^{-1})$	$K_{obs} (\mu g \cdot ml^{-1} \cdot h^{-1})$ + Sodium Citrate
15 Reference		- 0.1
Metal ion:		
Cr^{2+}	- 8.8	- 1.0
Fe^{3+}	- 6.1	- 2.0
20 Ni^{2+}	- 0.2	- 0.1
Zn^{2+}	- 0.7	

Addition of Cu^{2+} or Co^{2+} was not investigated as these ions caused precipitations in the solutions.

Degradation of Tiagabine Hydrochloride in Presence of Antioxidants

Table 3 shows the observed 0. order rate constants for degradation of tiagabine hydrochloride in solutions containing various antioxidants. It was chosen to study the effect of a combination of BHT, BHA and PG, because the three substances are known to have a synergistic antioxidant effect in food (Ref. 1).

The antioxidant effect of α -Tocopherol was superior to the antioxidant effect of Ascorbic Acid and "BHT, BHA and PG". The presence of Sodium Bisulfite reduced the stability of tiagabine hydrochloride in solutions.

Table 3: Degradation of 100 $\mu\text{g/ml}$ (0.2 $\mu\text{mol/ml}$) Tiagabine Hydrochloride, in 10 1% Hydrogen Peroxide and 60% Ethanol/Water by Adding of Antioxidants, 50°C

	$\mu\text{mol/ml}$	$K_{\text{obs}} (\mu\text{g}\cdot\text{ml}^{-1}\cdot\text{h}^{-1})$
Reference		- 0.12
BHT	0.45	- 0.05
15 BHA	0.55	
PG	0.47	
α -tocopherol	0.53	- 0.08
Ascorbic Acid	14.0	- 0.11
Sodium Bisulphite	14.0	- 0.34
20 BHT	0.45	- 0.09
BHA	0.55	
PG	0.47	
Ascorbic Acid	14.0	
α -tocopherol	0.53	Stable during testing
25 Ascorbyl Palmitate	0.60	

Combinations of the water soluble and the lipid soluble antioxidants did not

improve the stability of tiagabine hydrochloride. The combination of α -Tocopherol and Ascorbyl Palmitate made the tiagabine hydrochloride stable during the testing period. The synergistic effect of the two antioxidants is known from other systems (Ref. 2).

5 Conclusion

A model was set up for an evaluation within 24 hours of the effect of different metal ions, chelator and antioxidants on the stability of tiagabine hydrochloride in solutions.

The study indicates that adding of Sodium Citrate as Chelator and α -Tocopherol & Ascorbyl Palmitate as antioxidants to tiagabine hydrochloride in a relevant dosage form would increase the stability.

Initiating the formulation work of tiagabine hydrochloride in a relevant dosage form, a model is available for rapid screening of the influence of chelators and antioxidants on the stability of tiagabine hydrochloride.

15 References

- [1] T.E. Furis. Handbook of Food Additives. 2nd Edition. Volume I. CRC Press.
- [2] Marinova & Yanishlievd. Fat Sci. Technol. 94. Jahrgang no. 12. 1992. Page 448-452.

Tablets containing 0.04%, 0.4% and 1.0% per weight of tablet gross mass (320 mg) of α -tocopherol and propyl gallate, resp. where prepared as described in Example 1. The stability of the tablets were tested by storage at

40°C and 75% RH. Results are shown in Table 4, wherein degradation products are expressed as in table 1.

Table 4

Sum of Degradation Products in Tablets after Storage at 40°C/75% RH

5	Antioxidant	Concentration %	1 Month	3 Months
	<i>α</i> -Tocopherol	0.04	0.5	2.2
		0.4	0.3	1.1
		1.0	0.3	1.3
	Propyl gallate	0.04	0.4	1.5
		0.4	1.2	4.1
		1.0	1.1	3.9

CLAIMS

1. Pharmaceutical composition comprising
 - (a) tiagabine or a pharmaceutically acceptable salt thereof,
 - (b) one or more pharmaceutically acceptable antioxidants in an amount
5 sufficient to stabilize tiagabine or its pharmaceutically acceptable salt
and
 - (c) optionally a pharmaceutically acceptable carrier.
2. A composition according to claim 1 in the form of a powder or a tablet.
3. A composition according to claim 1 or 2, wherein the antioxidant is
10 selected from the group consisting of fat-soluble antioxidants.
4. A composition according to claim 1, 2 or 3 wherein the antioxidant is α -tocopherol.
5. A composition according to claim 1 or 2 wherein the antioxidant is ascorbic acid.
- 15 6. A composition according to claim 1 or 2 wherein the antioxidant is a mixture of a fat-soluble and a water-soluble antioxidant.
7. A composition according to claim 6 wherein the antioxidant is a mixture of α -tocopherol and ascorbyl palmitate.
8. A composition according to claim 1-7 wherein the amount of antioxi-
20 dant is from 5-25 parts by weight per 100 parts of tiagabine hydroch-
loride.

9. A process for the preparation of a composition according to claim 1 or 2 which comprises forming a mixture of:
- (a) tiagabine or a pharmaceutically acceptable salt thereof,
 - (b) one or more pharmaceutically acceptable antioxidants in an amount
5 sufficient to stabilize tiagabine or its pharmaceutically acceptable salt
and
 - (c) a pharmaceutically acceptable carrier.
10. A process for the preparation of a composition according to claim 1 or 2 which comprises:
- 10 (a) forming a mixture according to claim 9,
- (b) carry out a melt-granulation of the mixture using low temperature melting binders.
11. A process according to claim 9 or 10 characterized in that the steps are carried out at low water vapour pressure and low oxygen pressure.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/DK 96/00192

A. CLASSIFICATION OF SUBJECT MATTER

IPC6: A61K 31/445, A61K 31/355, A61K 31/375

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC6: A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

SE,DK,FI,NO classes as above

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,X	Proc. 1st World Meeting on Pharmaceuticals, Biopharmaceutics and Pharmaceutical Technology, Budapest, 9-11 May 1995, pages 951-952, H. Weibel et al, "Influence of Metal Ions, Chelator and Antioxidants on Tiagabine Stability in Solutions" -- -----	1-11



Further documents are listed in the continuation of Box C.



See patent family annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"B" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

26 August 1996

Date of mailing of the international search report

30 -08- 1996

Name and mailing address of the ISA/
 Swedish Patent Office
 Box 5055, S-102 42 STOCKHOLM
 Facsimile No. +46 8 666 02 86

Authorized officer

Göran Karlsson
 Telephone No. +46 8 782 25 00

THIS PAGE BLANK (USPTO)